RT Journal Article
SR Electronic
T1 Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.04.02.022764
DO 10.1101/2020.04.02.022764
A1 Mantlo, Emily
A1 Bukreyeva, Natalya
A1 Maruyama, Junki
A1 Paessler, Slobodan
A1 Huang, Cheng
YR 2020
UL http://biorxiv.org/content/early/2020/04/05/2020.04.02.022764.1.abstract
AB The ongoing historic outbreak of COVID-19 not only constitutes a global public health crisis, but also carries a devastating social and economic impact. The disease is caused by a newly identified coronavirus, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the remarkable sensitivity of SARS-CoV-2 to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α at a concentration of 50 international units (IU) per milliliter drastically reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-α and IFN-β treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potent efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.